Skip to main
CATX

CATX Stock Forecast & Price Target

CATX Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Perspective Therapeutics Inc is making significant strides in the radiopharmaceutical sector with its proprietary Lead-212 (212Pb) technology, which is expected to improve safety and efficacy in cancer treatment. The company's lead program, VMT-α-NET, demonstrates promising clinical data and is progressing towards registrational development, which could tap into a multi-billion-dollar market. Additionally, the planned expansion of manufacturing capabilities and a decentralized supply chain are poised to enhance commercial readiness and competitive positioning within the industry.

Bears say

Perspective Therapeutics Inc. faces significant risks that contribute to a negative outlook on its stock, primarily stemming from the potential for disappointing clinical data regarding its product candidates. Increased competition in the radiopharmaceutical sector could reduce the market potential and valuation of Perspective's offerings, particularly if rivals achieve greater clinical success or market penetration. Additionally, the company's ability to secure favorable reimbursement and adoption of its products is uncertain, which, combined with potential delays or failures in development due to partnerships, poses a substantial challenge to its financial stability and growth prospects.

CATX has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Perspective Therapeutics Inc (CATX) Forecast

Analysts have given CATX a Strong Buy based on their latest research and market trends.

According to 8 analysts, CATX has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Perspective Therapeutics Inc (CATX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.